PURPOSE: C-reactive protein (CRP), an inflammation marker, is associated with colorectal cancer (CRC) risk in some prospective studies. Whether increased CRP is indicative of colonic inflammation, a possible CRC cause, or of other sources of inflammation (e.g., adiposity), is unknown. Thus, we evaluated the association between CRP and colonic mucosal measures of inflammation. METHODS: 151 adults undergoing colonoscopy provided a blood sample and random left- and right-side colonic mucosal biopsies. Height and weight were measured, and lifestyle information was collected. High-sensitivity C-reactive protein (hsCRP) was measured by immunoturbidometric assay. A gastrointestinal pathologist evaluated biopsies for seven colonic inflammation measures. Of 119 participants with complete information, 24 had an inflammatory bowel disease (IBD) history and were analyzed separately. We calculated the number of colonic inflammation measures present in both biopsies, and separately for right and left biopsies. Adjusted geometric mean hsCRP was calculated using linear regression, overall, by demographic and lifestyle factors, and inflammation measures. RESULTS: Most participants had ≥ 1 colonic inflammation measure (0: 21 %, 1: 39 %, ≥ 2: 40 %). Adjusted mean hsCRP did not increase with increasing number of inflammation measures (0: 1.67; 1: 1.33; ≥ 2: 1.01 mg/L; p trend = 0.21). Obese (2.03 mg/L) and overweight (1.61 mg/L) participants had higher adjusted mean hsCRP than normal-weight participants (0.62 mg/L; p trend <0.0001). Patterns were similar for participants with a history of IBD. CONCLUSIONS: hsCRP concentration was not associated with colonic inflammation, although hsCRP increased with adiposity. The hsCRP-CRC association may be explained by residual confounding by other risk factors, such as adiposity, rather than by CRP marking colonic inflammation.
PURPOSE:C-reactive protein (CRP), an inflammation marker, is associated with colorectal cancer (CRC) risk in some prospective studies. Whether increased CRP is indicative of colonic inflammation, a possible CRC cause, or of other sources of inflammation (e.g., adiposity), is unknown. Thus, we evaluated the association between CRP and colonic mucosal measures of inflammation. METHODS: 151 adults undergoing colonoscopy provided a blood sample and random left- and right-side colonic mucosal biopsies. Height and weight were measured, and lifestyle information was collected. High-sensitivity C-reactive protein (hsCRP) was measured by immunoturbidometric assay. A gastrointestinal pathologist evaluated biopsies for seven colonic inflammation measures. Of 119 participants with complete information, 24 had an inflammatory bowel disease (IBD) history and were analyzed separately. We calculated the number of colonic inflammation measures present in both biopsies, and separately for right and left biopsies. Adjusted geometric mean hsCRP was calculated using linear regression, overall, by demographic and lifestyle factors, and inflammation measures. RESULTS: Most participants had ≥ 1 colonic inflammation measure (0: 21 %, 1: 39 %, ≥ 2: 40 %). Adjusted mean hsCRP did not increase with increasing number of inflammation measures (0: 1.67; 1: 1.33; ≥ 2: 1.01 mg/L; p trend = 0.21). Obese (2.03 mg/L) and overweight (1.61 mg/L) participants had higher adjusted mean hsCRP than normal-weight participants (0.62 mg/L; p trend <0.0001). Patterns were similar for participants with a history of IBD. CONCLUSIONS: hsCRP concentration was not associated with colonic inflammation, although hsCRP increased with adiposity. The hsCRP-CRC association may be explained by residual confounding by other risk factors, such as adiposity, rather than by CRP marking colonic inflammation.
Authors: Craig A Solem; Edward V Loftus; William J Tremaine; William S Harmsen; Alan R Zinsmeister; William J Sandborn Journal: Inflamm Bowel Dis Date: 2005-08 Impact factor: 5.325
Authors: Anna E Prizment; Kristin E Anderson; Kala Visvanathan; Aaron R Folsom Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-07 Impact factor: 4.254
Authors: Andrew Poullis; Russell Foster; Ajeya Shetty; Magne K Fagerhol; Michael A Mendall Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: Lisa C Hudgins; Thomas S Parker; Daniel M Levine; Bruce R Gordon; Stuart D Saal; Xian-Cheng Jiang; Cindy E Seidman; Jolanta D Tremaroli; Julie Lai; Albert L Rubin Journal: J Lipid Res Date: 2003-05-16 Impact factor: 5.922
Authors: Eleonor I Fransson; G David Batty; Adam G Tabák; Eric J Brunner; Meena Kumari; Martin J Shipley; Archana Singh-Manoux; Mika Kivimäki Journal: J Clin Endocrinol Metab Date: 2010-08-18 Impact factor: 5.958
Authors: Mingyang Song; Raaj S Mehta; Kana Wu; Charles S Fuchs; Shuji Ogino; Edward L Giovannucci; Andrew T Chan Journal: Cancer Prev Res (Phila) Date: 2015-10-28
Authors: Elizabeth D Kantor; Ruzan Udumyan; Lisa B Signorello; Edward L Giovannucci; Scott Montgomery; Katja Fall Journal: Gut Date: 2015-05-18 Impact factor: 23.059
Authors: Xiaoliang Wang; James Y Dai; Demetrius Albanes; Volker Arndt; Sonja I Berndt; Stéphane Bézieau; Hermann Brenner; Daniel D Buchanan; Katja Butterbach; Bette Caan; Graham Casey; Peter T Campbell; Andrew T Chan; Zhengyi Chen; Jenny Chang-Claude; Michelle Cotterchio; Douglas F Easton; Graham G Giles; Edward Giovannucci; William M Grady; Michael Hoffmeister; John L Hopper; Li Hsu; Mark A Jenkins; Amit D Joshi; Johanna W Lampe; Susanna C Larsson; Flavio Lejbkowicz; Li Li; Annika Lindblom; Loic Le Marchand; Vicente Martin; Roger L Milne; Victor Moreno; Polly A Newcomb; Kenneth Offitt; Shuji Ogino; Paul D P Pharoah; Mila Pinchev; John D Potter; Hedy S Rennert; Gad Rennert; Walid Saliba; Clemens Schafmayer; Robert E Schoen; Petra Schrotz-King; Martha L Slattery; Mingyang Song; Christa Stegmaier; Stephanie J Weinstein; Alicja Wolk; Michael O Woods; Anna H Wu; Stephen B Gruber; Ulrike Peters; Emily White Journal: Int J Epidemiol Date: 2019-06-01 Impact factor: 9.685